EUVIMEDEUVIMED entdecken
Crossref

Personalized mRNA Cancer Vaccines: Advancing Precision Oncology Through Neoantigen-Directed Immunotherapy

Fabio Camilo Jaramillo Contreras, Marlies Solís Rodríguez, Michelle Miranda Espejel Romero, José Alberto Pérez Pérez, José Antonio Reyes Pinto, Ricardo Harold Flores Arotinco, Jorge Angel Velasco Espinal, Alexa Fernanda Uriostegui Navarro

International Science Journal · 28.06.2026 · 3 (1)

DOI: 10.64784/241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Science Journal, online erschienen am 28.06.2026. Verfasst von Fabio Camilo Jaramillo Contreras und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The emergence of personalized messenger RNA (mRNA)-based cancer vaccines has introduced a novel therapeutic strategy capable of integrating genomic medicine, immunology, and biotechnology into precision oncology. The objective of this review was to analyze the current scientific evidence regarding the biological foundations, immunological mechanisms, clinical applications, advantages, limitations, and future perspectives of personalized mRNA cancer vaccines. A scientific method-based narrative review methodology was employed through a structured search of peer-reviewed literature indexed in PubMed, Scopus, Web of Science, ScienceDirect, SpringerLink, and other internationally recognized databases. The evidence demonstrated that personalized mRNA vaccines can encode patient-specific neoantigens, stimulate robust CD4+ and CD8+ T-cell responses, enhance dendritic-cell-mediated antigen presentation, and promote durable immunological memory. Clinical investigations have reported encouraging results in melanoma, pancreatic cancer, glioblastoma, lung cancer, and other malignancies, particularly when vaccines are combined with immune checkpoint inhibitors. The findings also revealed important advantages, including high therapeutic specificity, individualized treatment design, and rapid development capacity. However, challenges related to neoantigen selection, manufacturing costs, regulatory complexity, and healthcare infrastructure remain significant barriers to widespread implementation. From a regional perspective, countries such as Mexico, Colombia, and Ecuador are progressively expanding precision oncology capabilities, although important limitations persist regarding access to genomic technologies and advanced immunotherapies. Overall, personalized mRNA cancer vaccines represent a promising innovation with the potential to transform future cancer treatment through highly individualized and immune-based therapeutic approaches.

Zitieren

APA

Contreras, F. C. J., Rodríguez, M. S., Romero, M. M. E., Pérez, J. A. P., Pinto, J. A. R., Arotinco, R. H. F., Espinal, J. A. V., & Navarro, A. F. U. (2026). Personalized mRNA Cancer Vaccines: Advancing Precision Oncology Through Neoantigen-Directed Immunotherapy. International Science Journal, 3(1). https://doi.org/10.64784/241

Vancouver

Contreras FCJ, Rodríguez MS, Romero MME, Pérez JAP, Pinto JAR, Arotinco RHF, et al. Personalized mRNA Cancer Vaccines: Advancing Precision Oncology Through Neoantigen-Directed Immunotherapy. International Science Journal. 2026;3(1). doi:10.64784/241

BibTeX
@article{Contreras2026,
  author = {Contreras, Fabio Camilo Jaramillo and Rodríguez, Marlies Solís and Romero, Michelle Miranda Espejel and Pérez, José Alberto Pérez and Pinto, José Antonio Reyes and Arotinco, Ricardo Harold Flores and Espinal, Jorge Angel Velasco and Navarro, Alexa Fernanda Uriostegui},
  title = {Personalized mRNA Cancer Vaccines: Advancing Precision Oncology Through Neoantigen-Directed Immunotherapy},
  journal = {International Science Journal},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.64784/241}
}
Kostenlos starten →